TUSTIN, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient ...
Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs No significant ...
The efficacy of the suicide gene therapy using the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system for the treatment of cancer is limited because of the insufficient gene ...
Avid Bioservices has expanded its viral vector development and manufacturing facility with the addition of analytical and process development suites. Avid Bioservices, a biologics-focused contract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback